Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Eloy E. Ordaya, Elena Beam, Joseph D. Yao, Raymund R. Razonable, Paschalis Vergidis

Research output: Contribution to journalArticlepeer-review


Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

Original languageEnglish (US)
Article numberofac283
JournalOpen Forum Infectious Diseases
Issue number7
StatePublished - Jul 1 2022


  • COVID-19
  • immunocompromised hosts
  • monoclonal antibodies
  • transplant infectious diseases

ASJC Scopus subject areas

  • Oncology
  • Infectious Diseases

Cite this